Trends in the landscape of clinical trials of innovative drugs in China since 2015 www.nature.com/articles/d41... This analysis highlights how China has become a high-volume destination for clinical trials in the past decade, driven by regulatory modernization and capital investment

A new article in Nature Reviews Drug Discovery, inspired by discussions at previous International Drug Repurposing Conferences (iDR), explores how we can make the most of the potential of drug repurposing. 🔗 Read the article: https://bit.ly/4eyNFjq 🎟️ Register for iDR26: remedi4all.org/iDR26

The evolving landscape of obesity pharmacotherapy www.nature.com/articles/s41... rdcu.be/fiw7g This new Review covers the evolution of obesity pharmacotherapy from GLP1 receptor agonists to multi-receptor agonists, oral formulations, weight-loss quality approaches and tissue-specific drug targeting

Blood–brain barrier (BBB) dysfunction is a hallmark of many diseases of the brain, such as Alzheimer disease. This Review in the May issue covers strategies for BBB repair and protection in various diseases and during normal ageing rdcu.be/fij4F www.nature.com/articles/s41...

The ovarian cancer drug market www.nature.com/articles/d41... This new article analyses the pipeline of drugs in development for ovarian cancer, such as antibody-drug conjugates, and their expected impact on the market

First PROTAC gains FDA approval, bolstering targeted protein degradation and induced proximity ambitions www.nature.com/articles/d41...

Our May issue is live! Read about biologic targeted protein degraders, strategies for blood-brain barrier rejuvenation and repair, targeting extrachromosomal DNA in cancer, therapeutic targeting of neuroimmune mechanisms in neurodegeneration and more here nature.com/nrd/volumes/...

For readers interested in drug repurposing, this Review evaluates computational approaches to drug repurposing based on categorization of available resources into an online catalogue www.nature.com/articles/s41... rdcu.be/fhe2Z

Bridging boundaries: making drug repurposing the new normal nature.com/articles/d41... This new article discusses approaches to overcoming systemic challenges in drug repurposing, enabling the approach to contribute more to new therapies, especially for rare diseases

Shifts in pharma’s therapeutic area focus www.nature.com/articles/d41... This new article analyses the evolution of the therapeutic area focus of large pharmaceutical companies, as well as phase III resourcing and the composition of drug launches

Sarah Crunkhorn, Senior Editor at Nature Reviews Drug Discovery, will be attending the TIDES conference on oligonucleotide and peptide therapeutics in Boston on 11-14 May informaconnect.com/tides/ #TIDESUSA

The landscape for therapeutic cancer vaccines www.nature.com/articles/d41... This new article analyses the pipeline of clinical-stage therapeutic cancer vaccines, including the technology platforms, antigen selection and personalization approaches

Tumour-agnostic kinase inhibitors nature.com/articles/s41... rdcu.be/fgiHN For readers interested in kinase inhibitors, this Review covers small-molecule inhibitors that target kinase pathway aberrations as tumour‐agnostic agents

Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies rdcu.be/fgg49 nature.com/articles/s41... This new Review covers the expanding toolkit for kinase modulation, such as allosteric modulators and molecular glues

New review just out: Drs. Erik S. Knudsen, Agnieszka K. Witkiewicz, and Sheheryar Kabraji of @roswellpark.bsky.social outline the evolving landscape of CDK inhibition: from the success of CDK4/6 inhibitors in breast cancer to next-gen strategies expanding into other tumor types. #CDK #BreastCancer

For readers interested in advances with JAK inhibitors, this review in our April issue covers their application in immunological and haematological diseases, as well as the development of inhibitors of the downstream STAT family rdcu.be/ff5J9 www.nature.com/articles/s41...

Eli Lilly outlays $2.3bn to acquire blood cancer specialist Ajax Therapeutics, whose lead asset is a phase I oral once-daily Type II JAK2 inhibitor www.pharmaceutical-technology.com/news/eli-lil... #pharma

The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond www.nature.com/articles/s41... rdcu.be/ffR0W This new Review discusses how combination strategies, novel CDK2- and CDK4-selective inhibitors and biomarkers are addressing drug resistance and expanding therapeutic uses

For readers interested in wearable technologies in clinical trials for drug development, this Review discusses the characteristics of different classes of wearable technologies and analyses their use in drug trials rdcu.be/e9L7x nature.com/articles/s41...

For readers interested in the potential of in vivo CAR T therapies for cancer and autoimmune diseases, here's a comprehensive review rdcu.be/ffE1i nature.com/articles/s41...

In vivo CAR T purchase spree continues with Lilly deal worth up to US$7 billion www.nature.com/articles/d41... The deal is the biggest to date in the red-hot race to develop therapies that reprogram immune cells directly in patients for the treatment of cancer and autoimmune diseases

Systemic lupus erythematosus is one autoimmune disease for which CAR-T cell therapies have shown substantial promise in clinical trials. Find out more about therapeutic advances for lupus in this comprehensive review rdcu.be/ffcqI www.nature.com/articles/s41...

For readers interested in the promise and challenges for CAR-T cell therapies for autoimmune diseases, here's a comprehensive review from our April issue www.nature.com/articles/s41...

Realizing the promise of CAR-T cell therapies for autoimmune diseases www.nature.com/articles/d41... CAR-T cell therapies that deplete B cells could change the treatment paradigm in B cell-driven autoimmune diseases. This article discusses key considerations in realizing their potential

Biologic degraders push forward in the clinic www.nature.com/articles/d41... Antibody-based extracellular targeted protein degraders are advancing in the clinic, highlighting emerging opportunities to destroy disease-linked proteins in cancer and autoimmunity

Safety considerations for cereblon-recruiting targeted protein degraders rdcu.be/feDVy www.nature.com/articles/s41... Degradation of unintended neosubstrates of cereblon is a key safety concern for PROTACs and molecular glues. This new Perspective discusses how to approach it

Target identification and assessment in the era of AI rdcu.be/fep9Z www.nature.com/articles/s41... This new Review analyses advances in applying AI-driven approaches for therapeutic target exploration, and discusses how to address challenges and limitations in the field

This Review in the April issue covers promising drug targets for schizophrenia treatment that affect neurotransmitter systems, immune processes and inflammation rdcu.be/fdZNP www.nature.com/articles/s41...

FDA new drug approvals in Q1 2026 nature.com/articles/d41... Potential blockbusters approved in the first quarter include an oral IL-23 receptor inhibitor for psoriasis and a glucocorticoid receptor antagonist for various cancers

Where are the women’s health drugs? www.nature.com/articles/d41... Wendy Young, an advisor at Google Ventures and former head of small-molecule drug discovery at Genentech, discusses the dearth of women’s health drug discovery programmes

Amorphous solid dispersions and lipid-based formulations could help address delivery challenges for novel therapeutic modalities such as PROTACs and cyclic peptides - find out more about these formulation approaches here www.nature.com/articles/s41... rdcu.be/fdqdn

Unlocking biological barriers: nonclinical safety considerations for RNA-based complex biologics www.nature.com/articles/d41... Bioconjugated oligonucleotides (BCOs) could expand the applicability of RNA-based drugs. This article presents recommendations when advancing BCOs into the clinic

Developing disease-modifying drugs for osteoarthritis has been particularly challenging. Find out about progress with the pipeline in this news article in the April issue www.nature.com/articles/d41...

Our April issue is live! Read about drugs in development for osteoarthritis, the JAK-STAT pathway as a therapeutic target, novel drugs for schizophrenia, CAR T cell therapies for autoimmune diseases and more here www.nature.com/nrd/volumes/...

The PI3K pathway has key roles in cancer, immune regulation and genetic disorders. This Perspective discusses advances in understanding of PI3K signalling in disease and novel pharmacological strategies to target the pathway rdcu.be/faYxr www.nature.com/articles/s41...

For readers interested in lipid nanoparticles for oligonucleotide delivery, here's an article covering 60 years of progress in the field rdcu.be/fb9xD nature.com/articles/s41...

Our latest research highlight covers a paper in Nature on the design of lipid nanoparticles for delivery of mRNA to the pancreas nature.com/articles/d41...

For readers interested in GLP-1-based therapies for obesity and beyond, here's a comprehensive review www.nature.com/articles/s41... rdcu.be/fbrIE

FDA approves GLP-1 pill for obesity nature.com/articles/d41... Eli Lilly’s orforglipron is the first small-molecule GLP-1 receptor agonist to secure approval, offering a potential convenience edge over established peptidic GLP-1-based obesity drugs

The expanding role of formulations to enable oral delivery of poorly water-soluble drugs www.nature.com/articles/s41... rdcu.be/fbphx This new Review discusses how formulations can address delivery challenges for novel therapeutic modalities such as PROTACs and cyclic peptides

For readers interested in drug discovery for fibrotic diseases, here's a review on cross-organ biology and pathways to development of innovative drugs www.nature.com/articles/s41... rdcu.be/fbcDC

Our latest research highlight covers a paper in Cell identifying ROCK2 as a target for liver fibrosis and reporting an early-stage clinical trial of a selective ROCK2 inhibitor www.nature.com/articles/d41...

A renaissance in targeting the PI3K/AKT/mTOR pathway www.nature.com/articles/s41... rdcu.be/faYxr This new Perspective discusses how advances in understanding of PI3K signalling in disease and novel pharmacological strategies are revitalizing interest in targeting the pathway

For readers interested in novel drugs for chronic obstructive pulmonary disease, such as AstraZeneca's IL-33 inhibitor tozorakimab, here's a recent review www.nature.com/articles/s41... rdcu.be/faMN3

AstraZeneca’s COPD antibody gets Phase 3 wins in broader-than-expected population. endpoints.news/astrazenecas...

First-in-class blood–brain barrier shuttle wins FDA nod for Hunter syndrome www.nature.com/articles/d41... Denali Therapeutics’ tividenofusp alfa - an enzyme fused to a blood–brain barrier-penetrating Fc domain - showcases an emerging approach to better get complex drugs into the brain

The therapeutic potential of orphan adhesion G-protein-coupled receptors nature.com/articles/s41... rdcu.be/e52UX This Review discusses opportunities to target adhesion GPCRs in cancer, psychiatric disorders and autoimmune diseases, based on advances in structural biology

Wearable technologies in clinical trials for drug development: trends and emerging opportunities rdcu.be/e9L7x www.nature.com/articles/s41... This new Review summarizes the characteristics of classes of wearable technologies, and analyses their use in drug trials and the regulatory landscape

Can a first disease-modifying osteoarthritis drug make it past the FDA? www.nature.com/articles/d41... Biosplice says its dual CLK and DYRK kinase inhibitor reduces pain and slows joint damage. Up and coming localized gene therapies have the same goal

Alex Eccleston, Senior Editor at Nature Reviews Drug Discovery, will be attending the SMR conference ‘Target To Patient 2026’ on 20-21 April www.smr.org.uk/Meetings/202... @socmedres.bsky.social